These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 12710291

  • 1. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP, Ferrieres J, Grenier O, Boka G, Cantet C, Leizorovicz A.
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [Abstract] [Full Text] [Related]

  • 2. [Management of the cardiology patient with polyvascular disease: PRISMA study].
    Cournot M, Cambou JP, Ferrières J, Grenier O, Herrmann MA, Cantet C, Leizorovicz A.
    Arch Mal Coeur Vaiss; 2004 Sep; 97(9):841-8. PubMed ID: 15521475
    [Abstract] [Full Text] [Related]

  • 3. [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey].
    Jullien G, Mosnier M, Danchin N.
    Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):184-9. PubMed ID: 16104618
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease.
    Bongard V, Cambou JP, Lezorovcz A, Ferrères J, Vahanan A, Jullen G, Coppe G, Guerllot M, Herrmann MA, Mas JL.
    Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):394-402. PubMed ID: 15616412
    [Abstract] [Full Text] [Related]

  • 5. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sørensen HT, Johnsen SP.
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [Abstract] [Full Text] [Related]

  • 6. [Drug prescription in the post-percutaneous coronary interventions period: results of the ECART study].
    Philippe F, Sebaoun A, Avierinos C, Julien G.
    Ann Cardiol Angeiol (Paris); 2004 Jun; 53(3):131-6. PubMed ID: 15291168
    [Abstract] [Full Text] [Related]

  • 7. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T, Tricot O, Lemesle G, Deneve M, Lejeune P, Biausque F, Cordier C, Savoye C, Hennebert O, Taghipour K, Sivery B, Pruvost P, Alaoui M, Carpentier L, Segrestin B, Lamblin N, Bauters C.
    Arch Cardiovasc Dis; 2015 Jun; 108(6-7):340-6. PubMed ID: 25858539
    [Abstract] [Full Text] [Related]

  • 8. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
    Philippe F, Cambou JP, Danchin N, Thomas D.
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
    [Abstract] [Full Text] [Related]

  • 9. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.
    Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrières J, Schiele F, Simon T, Danchin N, Puymirat E, FAST-MI investigators.
    Eur J Prev Cardiol; 2019 Mar; 26(4):411-419. PubMed ID: 30354737
    [Abstract] [Full Text] [Related]

  • 10. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL.
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [Abstract] [Full Text] [Related]

  • 11. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC, Erskine N, McManus DD, Lessard D, Gore JM, Yarzebski J, Goldberg RJ.
    Am J Cardiol; 2016 Dec 15; 118(12):1792-1797. PubMed ID: 27743577
    [Abstract] [Full Text] [Related]

  • 12. Optimal medical management of peripheral arterial disease.
    Rice TW, Lumsden AB.
    Vasc Endovascular Surg; 2006 Dec 15; 40(4):312-27. PubMed ID: 16959725
    [Abstract] [Full Text] [Related]

  • 13. Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
    Erol MK, Kayıkçıoğlu M, Kılıçkap M, Arın CB, Kurt IH, Aktaş I, Güneş Y, Özkan E, Şen T, Ince O, Örnek E, Asoğlu R, Aladağ N, Zeybey U, Sinan ÜY, Dural M, Tüner H, Doğan A, Yenerçağ M, Akboğa M, Deveci OS, Somuncu MU.
    Anatol J Cardiol; 2020 Jul 15; 24(1):43-53. PubMed ID: 32628144
    [Abstract] [Full Text] [Related]

  • 14. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP, REACH Investigators.
    Crit Pathw Cardiol; 2009 Sep 15; 8(3):104-11. PubMed ID: 19726929
    [Abstract] [Full Text] [Related]

  • 15. Use of recommended medications after myocardial infarction in Austria.
    Winkelmayer WC, Bucsics AE, Schautzer A, Wieninger P, Pogantsch M, Pharmacoeconomics Advisory Council of the Austrian Sickness Funds.
    Eur J Epidemiol; 2008 Sep 15; 23(2):153-62. PubMed ID: 18064529
    [Abstract] [Full Text] [Related]

  • 16. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study.
    Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J, Michon P, Herrmann MA, Priollet P.
    J Vasc Surg; 2006 Aug 15; 44(2):314-8. PubMed ID: 16890860
    [Abstract] [Full Text] [Related]

  • 17. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH, Pereg D, Lishner M, Elis A.
    Harefuah; 2015 May 15; 154(5):299-302, 339-40. PubMed ID: 26168639
    [Abstract] [Full Text] [Related]

  • 18. ACE up the sleeve - are vascular patients medically optimized?
    Coveney AP, O'Brien GC, Fulton GJ.
    Vasc Health Risk Manag; 2011 Jan 07; 7():15-21. PubMed ID: 21339909
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of management of infarction in the Franche Comté province by the use of the Franche Comté Cardiology Registry, May 2005-May 2006].
    Schiele F, Fouché R, Lassabe G, Bohigas P, Magnin D, Bechetoille P, Thebault L, Faivre R, Boumal D, Frison J, Bassand JP, pour le réseau de cardiologie de Franche-Comté.
    Arch Mal Coeur Vaiss; 2007 Nov 07; 100(11):917-24. PubMed ID: 18209692
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.
    Gullón A, Suárez C, Díez-Manglano J, Formiga F, Cepeda JM, Pose A, Camafort M, Castiella J, Rovira E, Mostaza JM, en representación de los investigadores del estudio NONAVASC.
    Med Clin (Barc); 2017 Mar 03; 148(5):204-210. PubMed ID: 27993408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.